These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30747752)

  • 1. Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia: A Double-Blind, Placebo-Controlled Pilot Trial.
    Kucukgoncu S; Guloksuz S; Tek C
    J Clin Psychopharmacol; 2019; 39(2):182-184. PubMed ID: 30747752
    [No Abstract]   [Full Text] [Related]  

  • 2. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.
    Baum L; Lam CW; Cheung SK; Kwok T; Lui V; Tsoh J; Lam L; Leung V; Hui E; Ng C; Woo J; Chiu HF; Goggins WB; Zee BC; Cheng KF; Fong CY; Wong A; Mok H; Chow MS; Ho PC; Ip SP; Ho CS; Yu XW; Lai CY; Chan MH; Szeto S; Chan IH; Mok V
    J Clin Psychopharmacol; 2008 Feb; 28(1):110-3. PubMed ID: 18204357
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
    Singla V; Pratap Mouli V; Garg SK; Rai T; Choudhury BN; Verma P; Deb R; Tiwari V; Rohatgi S; Dhingra R; Kedia S; Sharma PK; Makharia G; Ahuja V
    J Crohns Colitis; 2014 Mar; 8(3):208-14. PubMed ID: 24011514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
    Yi Z; Fan X; Wang J; Liu D; Freudenreich O; Goff D; Henderson DC
    Psychiatry Res; 2012 Dec; 200(2-3):79-82. PubMed ID: 22727707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation.
    Satoskar RR; Shah SJ; Shenoy SG
    Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):651-4. PubMed ID: 3546166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
    Laan W; Grobbee DE; Selten JP; Heijnen CJ; Kahn RS; Burger H
    J Clin Psychiatry; 2010 May; 71(5):520-7. PubMed ID: 20492850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
    Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
    Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
    Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV
    CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment.
    Kelleher JP; Centorrino F; Huxley NA; Bates JA; Drake JK; Egli S; Baldessarini RJ
    Eur Neuropsychopharmacol; 2012 Jun; 22(6):415-8. PubMed ID: 22153972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.
    Goff DC; Leahy L; Berman I; Posever T; Herz L; Leon AC; Johnson SA; Lynch G
    J Clin Psychopharmacol; 2001 Oct; 21(5):484-7. PubMed ID: 11593073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Harvey PD; Siu CO; Romano S
    Psychopharmacology (Berl); 2004 Mar; 172(3):324-32. PubMed ID: 14615877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Bruno A; Pandolfo G; Micò U; Bellinghieri PM; Scimeca G; Cacciola M; Campolo D; Settineri S; Zoccali R
    J Psychopharmacol; 2011 May; 25(5):667-74. PubMed ID: 20615930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
    J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR; Pandolfo G; Micò U; Lamberti Castronuovo E; Abenavoli E; Scimeca G; Spina E; Zoccali R; Bruno A
    J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
    World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders.
    Breier A; Liffick E; Hummer TA; Vohs JL; Yang Z; Mehdiyoun NF; Visco AC; Metzler E; Zhang Y; Francis MM
    Schizophr Res; 2018 Sep; 199():395-402. PubMed ID: 29588126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
    Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
    Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.